NeuroXess
脑虎科技
Implantable flexible brain-computer interface company advancing clinical neural decoding
- Headquarters
- Shanghai, China
- Region
- Shanghai
- Founded
- 2021
- Stage
- Series A
Overview
NeuroXess was founded in October 2021 and is headquartered in Shanghai’s Huangpu district. It develops implantable flexible brain-computer interface (BCI) technology, using silk-protein electrode carriers that dissolve naturally after implantation to reduce immune response, with electrodes thinner than a human hair. Its 256-channel high-throughput flexible BCI system serves research and medical markets. In December 2024 it completed the world’s first real-time Chinese-language decoding and speech synthesis clinical trial, and in 2025 achieved the world’s first cross-region silent interaction. Founders include chief scientist Tao Hu, former deputy director of the Shanghai Institute of Microsystem and Information Technology (CAS), and co-founder/CEO Peng Lei. It was named to MIT Technology Review’s 50 Smartest Companies in 2022.
Products
3High-throughput Implantable Flexible BCI System
A 256-channel implantable flexible BCI system for research and medical use.
Digital EEG Machine
Class II medical device registered with China’s NMPA.
Silk-protein Flexible Electrodes
Bio-dissolvable electrode carriers that reduce immune response.
Highlights
3- 01Completed the world’s first real-time Chinese-language decoding and speech synthesis clinical trial in December 2024.
- 02Named to MIT Technology Review’s 50 Smartest Companies in 2022; won the WAIC SAIL Award in 2021.
- 03Building a BCI "super factory" in Jiangxi’s Ganjiang New Area, expected to be completed in H2 2026.
People
1
Funding
2- Source
A
Amount undisclosed
Events
0Not yet listed
Related projects
0Not yet listed
Topics
2Coverage
0Not yet listed
Information compiled from public sources; refer to the company's official website for authoritative details.